COVID-19的心脏受损：发病机制和诊断的问题

封面图片

如何引用文章

全文:

详细

冠状病毒感染仍然是医学界的一个热门话题。心脏结构受损从该病的异质性临床表现中脱颖而出，主要是炎性的。除心肌炎外，冠状病毒感染还可导致一系列急性或迟发性的心脏受损，如急性冠状动脉综合征、血栓栓塞性事件、心力衰竭和心律紊乱。众所周知，有心脏受损的病人的预后大幅度恶化。及时诊断和启动治疗对于严重并发症的预防至关重要。

本综述介绍了与COVID-19心脏受损发病机制有关的现代文献资料，讨论了利用现代技 术（实验室、功能、影像学），包括侵入性技术，对这种病理进行合理诊断的问题。在影像技术中起主要作用的是心脏超影磁共振成像。现在专家认为，与冠状病毒感染有关的心肌炎诊断，与其他心肌炎诊断相比，有一些根本区别。此外，还反映了与COVID-19疫苗接种相关的炎症性心脏受损的主要方面，因为这种并发症的发生率比通常认为的高。它往往是不打疫苗的一个理由，这对个人和整个人群都会产生严重的后果。

作者简介

Daria A. Filatova

Lomonosov Moscow State University

Email: dariafilatova.msu@mail.ru
ORCID iD: 0000-0002-0894-1994
SPIN 代码: 2665-5973
俄罗斯联邦, Moscow

Elena A. Mershina

Lomonosov Moscow State University; Medical Research and Education Center of Lomonosov Moscow State University

Email: elena_mershina@mail.ru
ORCID iD: 0000-0002-1266-4926
SPIN 代码: 6897-9641

MD, Cand. Sci. (Med), Associate Professor

俄罗斯联邦, Moscow; Moscow

Valentin E. Sinitsyn

Lomonosov Moscow State University; Medical Research and Education Center of Lomonosov Moscow State University

编辑信件的主要联系方式.
Email: vsini@mail.ru
ORCID iD: 0000-0002-5649-2193
SPIN 代码: 8449-6590

MD, Dr. Sci. (Med), Professor

俄罗斯联邦, Moscow; Moscow

参考

  1. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–810. doi: 10.1001/jamacardio.2020.0950
  2. Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533–546. doi: 10.1016/j.jacc.2020.06.007
  3. Lindner D, Fitzek A, Bräuninger H, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5(11):1–5. doi: 10.1001/jamacardio.2020.3551
  4. Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861–1862. doi: 10.1093/eurheartj/ehaa286
  5. Escher F, Pietsch H, Aleshcheva G, et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. 2020;7(5):2440–2447. doi: 10.1002/ehf2.12805
  6. Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911–915. doi: 10.1002/ejhf.1828
  7. Wichmann D. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020;173(12):1030. doi: 10.7326/L20-1206
  8. Buja LM, Wolf DA, Zhao B, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. 2020;(48):107233. doi: 10.1016/j.carpath.2020.107233
  9. Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: An autopsy series from New Orleans. Lancet Respir Med. 2020;10(7):681–686. doi: 10.1016/S2213-2600(20)30243-5
  10. Alijotas-Reig J, Esteve-Valverde E, Belizna C, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020;19(7):102569. doi: 10.1016/j.autrev.2020.102569
  11. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet Lond Engl. 2020;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5
  12. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973. doi: 10.1016/j.jacc.2020.04.031
  13. Choudry FA, Hamshere SM, Rathod KS, et al. High thrombus burden in patients with Covid-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76(10):1168–1176. doi: 10.1016/j.jacc.2020.07.022
  14. Bangalore S, Hamshere SM, Rathod KS, et al. ST-Segment elevation in patients with Covid-19: A case series. N Engl J Med. 2020;382(25):2478–2480. doi: 10.1056/NEJMc2009020
  15. Guglin ME, Etuk A, Shah C, et al. Fulminant myocarditis and cardiogenic shock following COVID-19 infection versus COVID-19 vaccination: A systematic literature review. J Clin Med. 2023;12(5):1849. doi: 10.3390/jcm12051849
  16. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585
  17. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17(9):1463–1471. doi: 10.1016/j.hrthm.2020.05.001
  18. Peretto G, Sala S, Rizzo S, et al. Ventricular arrhythmias in myocarditis: Characterization and relationships with myocardial inflammation. J Am Coll Cardiol. 2020;75(9):1046–1057. doi: 10.1016/j.jacc.2020.01.036
  19. Peretto G, Sala S, Rizzo S, et al. Arrhythmias in myocarditis: State of the art. Heart Rhythm. 2019;16(5):793–801. doi: 10.1016/j.hrthm.2018.11.024
  20. Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–1100. doi: 10.1093/cvr/cvaa078
  21. Asimaki A, Tandri H, Duffy ER, et al. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(5):743–752. doi: 10.1161/CIRCEP.111.964890
  22. Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2001;38(7):1773–1781. doi: 10.1016/s0735-1097(01)01654-0
  23. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1–9. doi: 10.1002/rmv.2141
  24. Modica G, Bianco M, Sollazzo F, et al. Myocarditis in athletes recovering from COVID-19: A systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(7):4279. doi: 10.3390/ijerph19074279
  25. Eichhorn C, Biere L, Schnell F, et al. Myocarditis in athletes is a challenge: Diagnosis, risk stratification, and uncertainties. JACC Cardiovasc Imaging. 2020;13(2):494–507. doi: 10.1016/j.jcmg.2019.01.039
  26. Azevedo RB, Botelho BG, de Hollanda G, et al. Covid-19 and the cardiovascular system: A comprehensive review. J Hum Hypertens. 2021;35(1):4–11. doi: 10.1038/s41371-020-0387-4
  27. Klok FA, Kruip MJ, van der Meer HJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;(191):145–147. doi: 10.1016/j.thromres.2020.04.013
  28. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. doi: 10.1001/jamacardio.2020.1017
  29. Larina OM. Cardiac magnetic resonance imaging in the diagnosis of acute myocarditis: A clinical case and review of the literature. Bulletin Radiol Radiol. 2014;(5):54–59. (In Russ).
  30. Arutyunov GB, Paleev FN, Moiseeva OM. Myocarditis in adults. Clinical recommendations 2020. Russ Cardiol J. 2021;26(11):4790. (In Russ). doi: 10.15829/1560-4071-2021-4790
  31. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: A JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–1487. doi: 10.1016/j.jacc.2009.02.007
  32. Tijmes SF, Thavendiranathan P, Udell JA, et al. Cardiac MRI assessment of nonischemic myocardial inflammation: State of the art review and update on myocarditis associated with COVID-19 Vaccination Radiol Cardiothorac Imaging. 2021;3(6):e210252. doi: 10.1148/ryct.210252
  33. Srichai MB, Lim RP, Lath N, et al. Diagnostic performance of dark-blood T2-weighted CMR for evaluation of acute myocardial injury. Invest Radiol. 2013;48(1):24–31. doi: 10.1097/RLI.0b013e3182718672
  34. Galán-Arriola C, Lim RP, Lath N, et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2019;73(7):779–791. doi: 10.1016/j.jacc.2018.11.046
  35. Blagova OV, Pavlenko EV, Varionchik NV, et al. Myocarditis as a natural phenomenon in patients with primary non-compact myocardium: Diagnosis, treatment and impact on outcomes // Russ J Cardiol. 2018;(2):44–52. (In Russ). doi: 10.15829/1560-4071-2018-2-44-52
  36. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33)2636–2648, 2648a–2648d. doi: 10.1093/eurheartj/eht210
  37. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19):2216–2233. doi: 10.1161/CIRCULATIONAHA.107.186093
  38. Aretz HT. Myocarditis: The Dallas criteria. Hum Pathol. 1987;18(6):619–624. doi: 10.1016/s0046-8177(87)80363-5
  39. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29(17):2073–2082. doi: 10.1093/eurheartj/ehn296
  40. Zhang M, Tavora F, Zhang Y, et al. The role of focal myocardial inflammation in sudden unexpected cardiac and noncardiac deaths: A clinicopathological study. Int J Legal Med. 2013;127(1):131–138. doi: 10.1007/s00414-011-0634-x
  41. Titov VA, Ignatyeva VS, Mitrofanova LB. Comparative study of informativeness of noninvasive methods for diagnosis of myocardial inflammatory diseases. Russ J Cardiol. 2018;23(2):53–59. (In Russ).
  42. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet Lond Engl. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3
  43. Mehta P, McAuley DF, Brown M, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet Lond Engl. 2020;395(10229):1033–1034. doi: 10.1016/S0140-6736(20)30628-0
  44. Castiello T, Georgiopoulos G, Finocchiaro G, et al. COVID-19 and myocarditis: A systematic review and overview of current challenges. Heart Fail Rev. 2022;27(1):251–261. doi: 10.1007/s10741-021-10087-9
  45. Mele D, Flamigni F, Rapezzi C, et al. Myocarditis in COVID-19 patients: Current problems. Intern Emerg Med. 2021;16(5):1123–1129. doi: 10.1007/s11739-021-02635-w
  46. Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: Cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol. 2021;(50):107300. doi: 10.1016/j.carpath.2020.107300
  47. Huang L, Zhao P, Tang D, et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging. 2020;13(11):2330–2339. doi: 10.1016/j.jcmg.2020.05.004
  48. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–1273. doi: 10.1001/jamacardio.2020.3557
  49. Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, et al. A novel circulating MicroRNA for the detection of acute myocarditis. N Engl J Med. 2021;384(21):2014–2027. doi: 10.1056/NEJMoa2003608
  50. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33. doi: 10.1038/s41392-020-0148-4
  51. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi: 10.1016/S2213-2600(20)30076-X
  52. Kawakami R, Sakamoto A, Kawai K, et al. Pathological evidence for SARS-CoV-2 as a cause of myocarditis. J Am Coll Cardiol. 2021;77(3):314–325. doi: 10.1016/j.jacc.2020.11.031
  53. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389
  54. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681. doi: 10.1016/S0140-6736(21)00234-8
  55. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577
  56. Voysey M, Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi: 10.1016/S0140-6736(20)32661-1
  57. Shiravi AA, Ardekani A, Sheikhbahaei E, et al. Cardiovascular complications of SARS-CoV-2 vaccines: An overview. Cardiol Ther. 2021;11(1):13–21. doi: 10.1007/s40119-021-00248-0
  58. Watad A, De Marco G, Mahajna H, et al. Immune-Mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 Vaccination: 5. Vaccines. 2021;9(5):435. doi: 10.3390/vaccines9050435
  59. Albert E, Aurigemma G, Saucedo J, et al. Myocarditis following COVID-19 vaccination. Radiol Case Rep. 2021;16(8):2142–2145. doi: 10.1016/j.radcr.2021.05.033
  60. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385(23):2140–2149. doi: 10.1056/NEJMoa2109730
  61. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132–2139. doi: 10.1056/NEJMoa2110737
  62. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–1090. doi: 10.1056/NEJMoa2110475

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Main mechanisms of structural damage in the heart of patients with COVID-19 and the clinical manifestations they cause.

下载 (274KB)
索引源数据
3. 图1。冠状病毒导致的心脏结构受损的主要机制及其引起的临床表现。

下载 (202KB)
索引源数据

版权所有 © Eco-Vector, 2023

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

##common.cookie##